K Street Braces for Bernie Sanders’ Takeover of Health Panel

Industry representatives are reportedly shifting tactics, preparing to lobby secondary committee members and progressive organizations to bypass the incoming chairman. Michaeleen Crowell, a lobbyist at S-3 Group and former chief of staff to Sanders, warned that the committee will no longer operate under the standard rules of influence. The primary fear among pharmaceutical and insurance lobbyists is the senator’s potential use of subpoena power, which could force high-level executives into public hearings, exposing corporate pay practices and pricing strategies to intense scrutiny.

While industry groups express anxiety over the potential revival of drug importation policies, public advocacy groups view the change as a long-overdue shift. Craig Holman of Public Citizen described the transition as a chance to balance the scales between corporate interests and the public good. Sanders, meanwhile, has signaled that he intends to use the committee’s investigative reach deliberately, citing the need to challenge what he characterizes as an era of unchecked corporate greed and predatory drug pricing.